The Latest Cardiac and Vascular News
New flow rate guidance designed to optimize irrigation and support consistent procedural outcomes 10,000+ VARIPULSE global procedures with low adverse event rate reinforces platform’s strong safety profile New Brunswick, NJ – July 14, 2025 – Today, Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, announced U.S. Food and Drug […]
FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it has received a purchase order from Centre Hospitalier Universitaire (CHU) de Rennes. This is the first purchase order from Universite de Rennes and marks the largest purchase order for the VIVO product line to date.
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to…
“Progress made in reducing heart attack deaths provides a roadmap to address rising mortality rates from arrythmias, heart failure and hypertensive heart disease” HOFFMAN ESTATES, Ill., July 3, 2025 /PRNewswire/ — Heart health leader OMRON Healthcare today issued an urgent health message…
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis’ MAGiC catheter.
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the Journal of Functional Biomaterials. Researchers from the Department of Cardiac Sciences at the Cumming School of Medicine found that the biomatrix in EluPro controlled inflammation and supported vascularization, key to a healthy device pocket with less scarring and risk of infection. Formation of a fibrotic capsule and bacterial colonization are known precursors to pocket infection, which can compromise both near-term procedural success and long-term pocket health following CIED implantation. The preclinical study demonstrated that EluPro stimulates early proangiogenic signals and reduced fibrosis over time. “What’s compelling is that we’re seeing not just a signal, but a clear biological effect,” said Dr. Paul W.M. Fedak, a professor and cardiac surgeon-scientist, and Director, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary. “The EluPro BioEnvelope initiates early proangiogenic signaling that promotes vascularization and healthier tissue integration — while simultaneously reducing fibrosis over time. This dual regenerative and protective response represents a meaningful step forward in improving outcomes for patients with implantable cardiac devices.” In mechanistic studies, fibroblasts, cells critical for tissue repair and healing, released significantly higher levels of growth and wound healing factors in the biomatrix environment compared to controls (p
IRVINE, Calif., July 1, 2025 /PRNewswire/ — EnChannel Medical Ltd., a global leader in cardiac electrophysiology innovation, today announced it has signed a definitive agreement to acquire the AcQMap™ High Resolution Imaging and Mapping platform assets from Acutus Medical Inc. The…
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators
Peer-reviewed research finds CADScor® strategy may reduce costs by up to $15.3M per 10,000 patients while safely ruling out heart disease OKLAHOMA CITY, June 26, 2025 /PRNewswire/ — Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new…
Volta Medical Secures U.S. Label Expansion for Volta AF-Xplorer Artificial Intelligence (AI) decision support system, clinically proven to help physicians treat underserved patients with persistent atrial fibrillation. MARSEILLE, France, June 11, 2025 /PRNewswire/ — Volta Medical, a…
